tanshinone has been researched along with galactose in 2 studies
| Studies (tanshinone) | Trials (tanshinone) | Recent Studies (post-2010) (tanshinone) | Studies (galactose) | Trials (galactose) | Recent Studies (post-2010) (galactose) |
|---|---|---|---|---|---|
| 1,445 | 10 | 1,033 | 18,988 | 193 | 4,605 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, X; He, A; Jiang, H; Johansson, M; Karlsson, A; Zhao, L; Zheng, C; Zheng, X | 1 |
| Deng, L; Hu, H; Hu, J; Hu, X; Zhang, J; Zheng, G | 1 |
2 other study(ies) available for tanshinone and galactose
| Article | Year |
|---|---|
Tanshinone IIA enhances bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in nuclei and mitochondria.
Topics: Abietanes; Animals; Bystander Effect; Cell Line, Tumor; Cell Nucleus; Connexin 26; Connexins; Deoxyuridine; Drosophila melanogaster; Galactose; Genetic Therapy; Genetic Vectors; Humans; Mitochondria; Nuclear Localization Signals; Osteosarcoma; Phosphotransferases (Alcohol Group Acceptor); Retroviridae; Thymine | 2015 |
Galactose-Modified PH-Sensitive Niosomes for Controlled Release and Hepatocellular Carcinoma Target Delivery of Tanshinone IIA.
Topics: Abietanes; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Galactose; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liposomes; Liver Neoplasms; Male; Mice; Random Allocation; Rats; Rats, Sprague-Dawley | 2021 |